Key result
The classification of pediatric cardiomyopathy remains phenotype-driven despite competing systems from the AHA and ESC, with the MOGE(S) system remaining unproven as a practical solution.
This review summarizes the evolution of cardiomyopathy classification systems in children, comparing the AHA and ESC frameworks and emphasizing the ongoing reliance on phenotype-driven clinical evaluation.
Answers are grounded in this paper and cite their sources.
Clinicians should retain phenotype-driven classification for pediatric cardiomyopathy; this review leaves open whether MOGE(S) improves practical utility.
There has been a progressive evolution in systems of classification for cardiomyopathy, driven by advances in imaging modalities, disease recognition, and genetics, following initial clinical descriptions in the 1960s. A pathophysiological classification emerged and was endorsed by World Health Organisation Task Forces in 1980 and 1995: dilated, hypertrophic, restrictive, and arrhythmogenic right ventricular cardiomyopathies; subdivided into idiopathic and disease-specific cardiomyopathies. Genetic advances have increasingly linked "idiopathic" phenotypes to specific mutations, although most linkages exhibit highly variable or little genotype-phenotype correlation, confounded by age-dependent changes and varying penetrance. The following two dominant classification systems are currently in use, with advocates in both continents. First, American Heart Association (2006): "A heterogeneous group of diseases of the myocardium associated with mechanical and/or electrical dysfunction that usually exhibit inappropriate ventricular hypertrophy or dilatation due to a variety of causes that frequently are genetic". These are subdivided to those predominantly involving the heart - primary - due to genetic mutation, including ion channelopathies, acquired disease, or mixed; and those with systemic involvement in other organ systems - secondary. Second, European Society of Cardiology (2008): "A myocardial disorder in which heart muscle is structurally and functionally abnormal… sufficient to cause the observed myocardial abnormality", with subdivision to familial and non-familial, excluding ion channelopathies, and split to specific disease subtypes and idiopathic. Further differences exist in the definitions for hypertrophic cardiomyopathy; however, whichever high-level classification is used, the clinical reality remains phenotype driven. Clinical evaluation and diagnostic imaging dominate initial patient contact, revealing diagnostic red flags that determine further specific tests. Genetic testing is undertaken early. A recent attempt to harmonise these competing systems named the MOGE(S) system, based on descriptive logical nosology, currently remains unproven as a fully practical solution.
No takes yet. Share an insight, caveat, or question.
Konta et al. (2015) conducted a review in Cardiomyopathy in children. The classification of pediatric cardiomyopathy remains phenotype-driven despite competing systems from the AHA and ESC, with the MOGE(S) system remaining unproven as a practical solution.
Synapse has enriched 10 related papers. Consider them for comparative context: